MX347961B - Formulaciones de liberación inmediata resistentes a alteración. - Google Patents
Formulaciones de liberación inmediata resistentes a alteración.Info
- Publication number
- MX347961B MX347961B MX2014003192A MX2014003192A MX347961B MX 347961 B MX347961 B MX 347961B MX 2014003192 A MX2014003192 A MX 2014003192A MX 2014003192 A MX2014003192 A MX 2014003192A MX 347961 B MX347961 B MX 347961B
- Authority
- MX
- Mexico
- Prior art keywords
- core
- dosage form
- immediate release
- release formulations
- tamper resistant
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000004888 barrier function Effects 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003349 gelling agent Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535758P | 2011-09-16 | 2011-09-16 | |
| PCT/IB2012/001916 WO2013038268A1 (en) | 2011-09-16 | 2012-09-14 | Tamper resistant immediate release formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014003192A MX2014003192A (es) | 2015-04-13 |
| MX347961B true MX347961B (es) | 2017-05-19 |
Family
ID=48577967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014003192A MX347961B (es) | 2011-09-16 | 2012-09-14 | Formulaciones de liberación inmediata resistentes a alteración. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140294947A1 (enExample) |
| EP (2) | EP2755638B1 (enExample) |
| JP (1) | JP6138798B2 (enExample) |
| AU (1) | AU2012310251B2 (enExample) |
| ES (2) | ES2583132T3 (enExample) |
| IL (1) | IL231482A (enExample) |
| MX (1) | MX347961B (enExample) |
| WO (1) | WO2013038268A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| WO2004084868A1 (en) | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| BR112015000150A2 (pt) | 2012-07-06 | 2017-06-27 | Egalet Ltd | composições farmacêuticas dissuasoras de abuso de liberação controlada |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US20200289424A1 (en) * | 2017-10-02 | 2020-09-17 | Purdue Pharma L.P. | Pharmaceutical compositions comprising delayed release gelling agent compositions |
| EP3727384A4 (en) | 2017-12-20 | 2021-11-03 | Purdue Pharma L.P. | ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401894D0 (en) * | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
| AU2003271024A1 (en) * | 2002-09-21 | 2004-04-08 | Jin Wang | Sustained release compound of acetamidophenol and tramadol |
| ATE549015T1 (de) * | 2003-10-31 | 2012-03-15 | Hexal Ag | Pharmazeutische wirkstoffhaltige formulierung mit überzug |
| CA2548834C (en) * | 2003-12-09 | 2009-08-11 | Euro-Celtique S.A. | Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| TW201509943A (zh) | 2004-03-30 | 2015-03-16 | Euro Celtique Sa | 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 |
| US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| US8652529B2 (en) * | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
| US9023400B2 (en) * | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
| SI2719378T1 (sl) * | 2006-06-19 | 2016-11-30 | Alpharma Pharmaceuticals Llc | Farmacevtski sestavki |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| AU2008286914B2 (en) * | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| US20090087487A1 (en) * | 2007-08-21 | 2009-04-02 | Michael Fox | Paliperidone sustained release formulation |
| US20110123575A1 (en) * | 2008-06-02 | 2011-05-26 | Dr. Reddy's Laboratories Ltd. | Modified release niacin formulations |
| PH12013501345A1 (en) * | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| EA201400172A1 (ru) * | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
-
2012
- 2012-09-14 ES ES12772421.9T patent/ES2583132T3/es active Active
- 2012-09-14 JP JP2014530332A patent/JP6138798B2/ja active Active
- 2012-09-14 MX MX2014003192A patent/MX347961B/es active IP Right Grant
- 2012-09-14 WO PCT/IB2012/001916 patent/WO2013038268A1/en not_active Ceased
- 2012-09-14 US US14/344,271 patent/US20140294947A1/en not_active Abandoned
- 2012-09-14 AU AU2012310251A patent/AU2012310251B2/en active Active
- 2012-09-14 ES ES16167881T patent/ES2703688T3/es active Active
- 2012-09-14 EP EP12772421.9A patent/EP2755638B1/en active Active
- 2012-09-14 EP EP16167881.8A patent/EP3078370B1/en active Active
-
2014
- 2014-03-12 IL IL231482A patent/IL231482A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20140294947A1 (en) | 2014-10-02 |
| EP3078370B1 (en) | 2018-11-07 |
| EP2755638B1 (en) | 2016-06-01 |
| WO2013038268A8 (en) | 2013-06-13 |
| WO2013038268A1 (en) | 2013-03-21 |
| EP3078370A1 (en) | 2016-10-12 |
| JP6138798B2 (ja) | 2017-05-31 |
| AU2012310251A1 (en) | 2013-05-09 |
| ES2703688T3 (es) | 2019-03-12 |
| AU2012310251A8 (en) | 2013-06-20 |
| MX2014003192A (es) | 2015-04-13 |
| JP2014530185A (ja) | 2014-11-17 |
| EP2755638A1 (en) | 2014-07-23 |
| AU2012310251B2 (en) | 2016-01-21 |
| IL231482A (en) | 2017-03-30 |
| ES2583132T3 (es) | 2016-09-19 |
| IL231482A0 (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX347961B (es) | Formulaciones de liberación inmediata resistentes a alteración. | |
| MX2014003186A (es) | Formulaciones farmacéuticas resistentes a la manipulación. | |
| NZ629468A (en) | Tamper resistant immediate release formulations | |
| PH12015501756A1 (en) | Tamper resistant pharmaceutical formulations | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| MX2009004871A (es) | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. | |
| MY162175A (en) | Aqueous drug delivery system | |
| WO2011107855A3 (en) | Sustained release oral liquid suspension dosage form | |
| TN2015000326A1 (en) | Tamper resistant pharmaceutical formulations | |
| WO2012091523A8 (en) | Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof | |
| SG10201901167SA (en) | Methods and compositions for treatment of attention deficit disorder | |
| MX366159B (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| WO2012052853A3 (en) | Oral dosing device for administration of medication | |
| NZ595046A (en) | Compositions and methods for extended therapy with aminopyridines | |
| JP2015505541A5 (enExample) | ||
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| WO2011084316A3 (en) | Formulations and methods for controlling mdi particle size delivery | |
| DE602008006700D1 (enExample) | ||
| MX394276B (es) | Inhalador de polvo seco y metodo de uso | |
| MX2016007181A (es) | Medicamentos inhalables. | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| EA200971113A1 (ru) | Шипучие таблетки для ингаляционного применения | |
| UA80243U (ru) | Система доставки лекарств | |
| IN2013MU03390A (enExample) | ||
| UA79903U (en) | pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |